Construction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype І

Qian, Ping; Zhi, Xianwei; Wang, Bo; Zhang, Huawei; Chen, Huanchun; Li, Xiangmin

doi:10.1186/s12985-015-0449-3

Cited by 13 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the emergence of the GI virus as the dominant genotype in Asian regions and the partial cross-protection efficacy of GIII-derived vaccines against GI viral infection, development of a GI-derived vaccine has been proposed to control GI viral infection [25,28,29]. We therefore examined the protective efficacy of a GI-derived vaccine against the challenge of GI and GIII viruses.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

et al. 2019

View full text Add to dashboard Cite

Genotype III (GIII) Japanese encephalitis virus (JEV) predominance has gradually been replaced by genotype I (GI) over the last 20 years in many Asian countries. This genotype shift raises concerns about the protective efficacy of Japanese encephalitis (JE) vaccines, as all of the currently licensed JE vaccines are derived from GIII strains. In this study, we conducted vaccination-challenge protection assays to evaluate the cross-protective efficacy of GI- or GIII-derived vaccines against the challenge of a heterologous genotype using a mouse challenge model. Titration of the neutralizing antibodies elicited by SA14-14-2 live-attenuated JE vaccine (SA14-14-2 vaccine), a GIII-derived vaccine, indicated that the titer of neutralizing antibodies specific to heterologous genotype GI stain was significantly lower than that specific to homologous genotype GIII strain in both pigs and mice immunized with the SA14-14-2 vaccine. Vaccination of mice with SA14-14-2 vaccine or a GIII-inactivated vaccine at high and medium doses completely protected vaccinated mice against challenge with the homologous genotype GIII strains, but failed to provide the vaccinated mice complete protection against the challenge of heterologous genotype GI strains. The protection rates against GI strain challenge were 60%–80%, showing that these vaccines were partially protective against GI strain challenge. Additionally, vaccination of mice with a GI-inactivated vaccine conferred 100% protection against the challenge of homologous genotype GI strains, but 50%–90% protection against the challenge of heterologous genotype GIII strains, showing a reduced protective efficacy of a GI-derived vaccine against GIII strain challenge. Overall, these observations demonstrated a partial cross-protection between GI and GIII strains and suggested a potential need for new JE vaccine strategies, including options like a bivalent vaccine, to control both genotype infection.

show abstract

Section: Resultsmentioning

confidence: 99%

“…These epidemiological data together with the reduced protective efficacy of GIII-derived vaccines against GI virus infection suggest a potential need for a GI-derived vaccine. In fact, several trials for the development of a GI-derived vaccine have been reported [25,28,29].…”

Section: Discussionmentioning

confidence: 99%

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…3D ) in pigs. Two GI JEV vaccine candidates, inactivated and recombinant pseudorabies virus expressing GI JEV VLPs, exhibited high homologous neutralizing activity against GI virus but were untested against GIII virus in mouse and pig models 54 , 55 . Here we showed that our GI VLPs exhibited high immunogenicity against GI virus in mice and also potent neutralizing antibodies against GII, GIII, and GIV viruses.…”

Section: Discussionmentioning

confidence: 99%

Genotype I of Japanese Encephalitis Virus Virus-like Particles Elicit Sterilizing Immunity against Genotype I and III Viral Challenge in Swine

Fan

Chen

Lin

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Swine are a critical amplifying host involved in human Japanese encephalitis (JE) outbreaks. Cross-genotypic immunogenicity and sterile protection are important for the current genotype III (GIII) virus-derived vaccines in swine, especially now that emerging genotype I (GI) JE virus (JEV) has replaced GIII virus as the dominant strain. Herein, we aimed to develop a system to generate GI JEV virus-like particles (VLPs) and evaluate the immunogenicity and protection of the GI vaccine candidate in mice and specific pathogen-free swine. A CHO-heparan sulfate-deficient (CHO-HS(-)) cell clone, named 51-10 clone, stably expressing GI-JEV VLP was selected and continually secreted GI VLPs without signs of cell fusion. 51-10 VLPs formed a homogeneously empty-particle morphology and exhibited similar antigenic activity as GI virus. GI VLP-immunized mice showed balanced cross-neutralizing antibody titers against GI to GIV viruses (50% focus-reduction micro-neutralization assay titers 71 to 240) as well as potent protection against GI or GIII virus infection. GI VLP-immunized swine challenged with GI or GIII viruses showed no fever, viremia, or viral RNA in tonsils, lymph nodes, and brains as compared with phosphate buffered saline-immunized swine. We thus conclude GI VLPs can provide sterile protection against GI and GIII viruses in swine.

show abstract

“…( 2015 ) Between gE and gI gene gE/TK -deleted strain prM and E genes of JEV Provided 100% and 80% protection against PRV and JEV infection, respectively (mice) Qian et al . ( 2015 ) Between gE and gI gene gE/gI -deleted strain E2 gene of CSFV Provided complete protection against maternal PRV and CSFV infection (pig) Wang YM et al . ( 2015 ) gE/gI/TK -deleted TJ strain Lei JL et al .…”

Section: Main Vaccines Against Prv Infectionmentioning

confidence: 99%

Current Status and Challenge of Pseudorabies Virus Infection in China

et al. 2021

View full text Add to dashboard Cite

Pseudorabies (PR), also called Aujeszky’s disease, is a highly infectious disease caused by pseudorabies virus (PRV). Without specific host tropism, PRV can infect a wide variety of mammals, including pig, sheep, cattle, etc., thereby causing severe clinical symptoms and acute death. PRV was firstly reported in China in 1950s, while outbreaks of emerging PRV variants have been documented in partial regions since 2011, leading to significant economic losses in swine industry. Although scientists have been devoting to the design of diagnostic approaches and the development of vaccines during the past years, PR remains a vital infectious disease widely prevalent in Chinese pig industry. Especially, its potential threat to human health has also attracted the worldwide attention. In this review, we will provide a summary of current understanding of PRV in China, mainly focusing on PRV history, the existing diagnosis methods, PRV prevalence in pig population and other susceptible mammals, molecular characteristics, and the available vaccines against its infection. Additionally, promising agents including traditional Chinese herbal medicines and novel inhibitors that may be employed to treat this viral infection, are also discussed.

show abstract

Construction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype І

Cited by 13 publications

References 45 publications

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

Partial cross-protection between Japanese encephalitis virus genotype I and III in mice

Genotype I of Japanese Encephalitis Virus Virus-like Particles Elicit Sterilizing Immunity against Genotype I and III Viral Challenge in Swine

Current Status and Challenge of Pseudorabies Virus Infection in China

Contact Info

Product

Resources

About